Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enhabit, Inc. (NYSE: EHAB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a public issuer. Enhabit, which operates as Enhabit Home Health & Hospice, files reports with the U.S. Securities and Exchange Commission that describe its home health and hospice business, financial performance, governance matters, and executive compensation arrangements.
Through its Form 8-K filings, Enhabit reports material events such as quarterly earnings releases, participation in investor conferences, leadership changes, and stockholder meeting results. For example, the company has filed 8-Ks to furnish its earnings press releases and supplemental information for quarters ended March 31, June 30, and September 30, as well as to describe a CEO transition plan, retention awards for senior officers, and approval of the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan at its annual meeting.
Enhabit’s filings also identify its common stock as registered under Section 12(b) of the Exchange Act and traded on the New York Stock Exchange under the symbol EHAB. The company uses its SEC reports to explain its use of non-GAAP measures such as Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted EPS, and Adjusted free cash flow, and to discuss how unusual or nonrecurring items affect the reconciliation to GAAP results. Same-store comparison methodology for home health and hospice locations is also described in these materials.
On this page, users can review Enhabit’s SEC filings in chronological order, including 8-Ks that detail results of operations and financial condition, regulation FD disclosures, equity plan approvals, and stockholder voting outcomes. Stock Titan’s tools surface these documents alongside AI-powered summaries that highlight key points, helping readers quickly understand how each filing relates to Enhabit’s home health and hospice operations, capital structure, and governance.
Investors and researchers can use this filings archive to follow Enhabit’s reported net service revenue trends, segment performance, executive and director arrangements, and the regulatory context around its home-based care business, all sourced from the company’s official submissions to the SEC’s EDGAR system.
Enhabit (NYSE:EHAB) filed a Form 4 disclosing that director Jeffrey Bolton purchased 15,773 common shares on 26 Jun 2025 at $9.51 each. The acquisition lifted his direct ownership to 123,395 shares, approximately a 15 % increase from his pre-transaction position. No dispositions or derivative securities were reported and the filing does not note any Rule 10b5-1 trading plan. Because Form 4 reports relate solely to insider activity, the document contains no financial statements, risk factors or operational updates.
Enhabit (NYSE:EHAB) filed an 8-K reporting results of its 26 June 2025 annual meeting. Shareholders approved the 2025 Equity & Incentive Compensation Plan, reserving up to 3.3 million shares (≈6.5% of the 50.6 million outstanding) for options, RSUs and performance awards. The plan, administered by the Compensation & Human Capital Committee, includes a $750k annual cap on non-employee director pay and allows performance metrics spanning EBITDA, revenue and quality-of-care. All 10 directors were re-elected, PwC was ratified as auditor and the say-on-pay resolution passed. Support for the equity plan was strong at 31.0 M for vs 0.4 M against. While the plan aligns incentives, it introduces potential dilution and higher stock-based compensation expense.
Enhabit, Inc. (ticker EHAB) has filed a Form S-8 with the SEC to register 3,289,042 shares of common stock for issuance under its newly approved 2025 Equity and Incentive Compensation Plan. The plan was authorized by shareholders at the 2025 Annual Meeting held on June 26, 2025. The filing incorporates the company’s most recent FY-2024 Form 10-K, Q1-2025 Form 10-Q, and prior descriptions of common stock by reference, ensuring that future periodic reports will automatically update the prospectus information.
The document outlines standard Delaware indemnification provisions for directors and officers, confirms the existence of D&O insurance, and lists required exhibits—most notably the full plan text (Exhibit 4.3) and an auditor consent from PwC (Exhibit 23.1). No new financial performance data, earnings guidance, or transactional details are disclosed, and the filing does not alter previously reported financial statements.
For investors, the primary implication is potential dilution from future equity grants as the registered shares become available for employee compensation. The filing is routine for public companies implementing stock-based incentive programs and does not, by itself, signal a change in the company’s operating outlook.